Brokerages forecast that Vital Therapies Inc (NASDAQ:VTL) will announce earnings per share (EPS) of ($0.30) for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Vital Therapies’ earnings. Vital Therapies posted earnings of ($0.37) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 18.9%. The business is scheduled to announce its next quarterly earnings report on Tuesday, March 6th.
According to Zacks, analysts expect that Vital Therapies will report full year earnings of ($1.27) per share for the current year, with EPS estimates ranging from ($1.27) to ($1.26). For the next fiscal year, analysts anticipate that the firm will report earnings of ($1.27) per share, with EPS estimates ranging from ($1.33) to ($1.21). Zacks’ earnings per share averages are an average based on a survey of research firms that follow Vital Therapies.
A number of equities analysts have recently commented on VTL shares. Raymond James Financial reissued a “buy” rating on shares of Vital Therapies in a research report on Tuesday, December 5th. Zacks Investment Research downgraded Vital Therapies from a “hold” rating to a “sell” rating in a research report on Tuesday, October 31st. ValuEngine downgraded Vital Therapies from a “sell” rating to a “strong sell” rating in a research report on Friday, November 17th. Finally, BidaskClub raised Vital Therapies from a “sell” rating to a “hold” rating in a research report on Wednesday, January 31st. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and one has given a buy rating to the company. Vital Therapies has a consensus rating of “Hold” and an average target price of $6.00.
Shares of Vital Therapies (NASDAQ VTL) traded down $0.20 during trading on Thursday, hitting $5.30. The stock had a trading volume of 154,375 shares, compared to its average volume of 185,240. Vital Therapies has a 1-year low of $2.25 and a 1-year high of $6.70. The firm has a market capitalization of $232.14, a P/E ratio of -3.93 and a beta of 4.76.
In other Vital Therapies news, Director Muneer A. Satter bought 100,000 shares of the firm’s stock in a transaction that occurred on Wednesday, December 13th. The stock was purchased at an average price of $5.48 per share, for a total transaction of $548,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Muneer A. Satter bought 50,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 7th. The shares were acquired at an average price of $4.77 per share, with a total value of $238,500.00. The disclosure for this purchase can be found here. Over the last three months, insiders have bought 300,000 shares of company stock valued at $1,520,000. Corporate insiders own 32.60% of the company’s stock.
A number of hedge funds have recently bought and sold shares of the stock. Victory Capital Management Inc. lifted its stake in Vital Therapies by 12.4% during the fourth quarter. Victory Capital Management Inc. now owns 2,925,886 shares of the company’s stock worth $17,409,000 after purchasing an additional 322,797 shares during the last quarter. Bank of Montreal Can purchased a new stake in Vital Therapies during the fourth quarter worth approximately $118,000. Granahan Investment Management Inc. MA lifted its stake in Vital Therapies by 51.4% during the third quarter. Granahan Investment Management Inc. MA now owns 388,282 shares of the company’s stock worth $1,961,000 after purchasing an additional 131,828 shares during the last quarter. Dimensional Fund Advisors LP purchased a new stake in Vital Therapies during the third quarter worth approximately $116,000. Finally, JPMorgan Chase & Co. lifted its stake in Vital Therapies by 1,985.3% during the third quarter. JPMorgan Chase & Co. now owns 25,462 shares of the company’s stock worth $123,000 after purchasing an additional 24,241 shares during the last quarter. Hedge funds and other institutional investors own 24.35% of the company’s stock.
WARNING: This article was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/02/09/brokerages-expect-vital-therapies-inc-vtl-to-post-0-30-earnings-per-share.html.
Vital Therapies Company Profile
Vital Therapies, Inc is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant.
Get a free copy of the Zacks research report on Vital Therapies (VTL)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vital Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies and related companies with MarketBeat.com's FREE daily email newsletter.